S'abonner

Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise - 14/12/17

Doi : 10.1016/j.jaad.2017.02.030 
Scott A. Elman, MD a, Cara Joyce, PhD b, Filippa Nyberg, MD c, Fukumi Furukawa, MD d, Mark Goodfield, MD e, Minoru Hasegawa, MD f, Branka Marinovic, MD g, Jacek C. Szepietowski, MD h, Jan Dutz, MD, FRCPC i, Victoria P. Werth, MD j, Joseph F. Merola, MD, MMSc a, k,
a Harvard Medical School, Boston, Massachusetts 
b Department of Public Health Sciences, Loyola University, Chicago, Illinois 
c Institution for Clinical Sciences, Karolinska Institutet at Danderyd Hospital, Stockholm, Sweden 
d Department of Dermatology, Wakayama Medical University, Wakayama, Japan 
e Department of Dermatology, Leeds General Infirmary, Leeds, United Kingdom 
f Department of Dermatology, Division of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan 
g Department of Dermatology and Venereology, University Hospital Center Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia 
h Department of Dermatology, Venereology, and Allergology, University of Medicine, Wroclaw, Poland 
i Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada 
j Philadelphia Department of Veterans Affairs Medical Center and Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 
k Division of Rheumatology, Departments of Dermatology and Medicine, Brigham and Women's Hospital, Boston, Massachusetts 

Reprint requests: Joseph F. Merola, MD, MMSc, Department of Dermatology, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115.Department of DermatologyBrigham and Women's Hospital221 Longwood AveBostonMA02115

Abstract

Background

No classification criteria currently exist for discoid lupus erythematosus (DLE), which has led to problematic heterogeneity in both observational and interventional research efforts.

Objectives

We sought to develop DLE classification criteria based on consensus of international expert opinion of relevant stakeholders in the field.

Methods

Using a Delphi consensus process and nominal group techniques, potential items for classification criteria were generated. Experts ranked items in terms of their appropriateness and ability to discriminate DLE from other diagnoses, and items were subsequently eliminated using consensus exercises.

Results

A final list of 12 clinical and histopathologic items was generated for potential inclusion into a set of DLE classification criteria through a formal ongoing validation process.

Limitations

The participants are predominantly composed of DLE experts in North America and Europe.

Conclusion

This work represents a key step toward the development of formal DLE classification criteria.

Le texte complet de cet article est disponible en PDF.

Key words : classification criteria, connective tissue diseases, cutaneous lupus erythematosus, Delphi method, discoid lupus erythematosus, lupus

Abbreviations used : ACR, CLE, DLE, EULAR, NGT


Plan


 Drs Werth and Merola are co-senior authors.
 Supported by the Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development to Dr Werth) and departmental funds from the Brigham and Women's Hospital Department of Dermatology. Celgene supported our meeting at the World Congress of Dermatology 2015.
 Disclosure: Dr Merola is a consultant for Biogen IDEC, Amgen, AbbVie, and Eli Lilly, and licensed a questionnaire to AbbVie. He has received grants from Biogen IDEC. Dr Szepietowski is a consultant for AbbVie, Biogenetica International Laboratories, LEO Pharma, Merck-Serono, Novartis, Pierre-Fabre, Sandoz, and Toray Corporation, and is a speaker for AbbVie, Astellas, Actavis, Adamed, Berlin-Chemie Mennarini, Bioderma, Fresenius, Janssen-Cilag, LEO Pharma, Takeda, and Vichy. Dr Nyberg is a consultant for Biogen. Dr Dutz is a consultant and speaker for Janssen-Ortho, AbbVie, Amgen, LEO Pharma, Celgene, Roche, and Novartis, and has received grants from AbbVie and Celgene. Dr Goodfield is a consultant for AbbVie, Janssen, Novartism, and Celgene, and is a speaker for AbbVie, Janssen, and LEO Pharma. He has received funding from Janssen, Pfizer, Novartis, LEO Pharma, and AbbVie. Dr Werth is a consultant for Biogen, Resolve Therapeutics, Celgene, Janssen, Genentech, Idera, Principia, Pfizer, Momenta, Medimmune, Xoma, Cipher, Lilly, TGMallincrodt, and Syntimmune. She has received grants from Biogen, Celgene, Genentech, Janssen, and Corbus Pharmaceuticals. Drs Elman, Joyce, Furukawa, Hasegawa, and Marinovic have no conflicts of interest to declare.


© 2017  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 77 - N° 2

P. 261-267 - août 2017 Retour au numéro
Article précédent Article précédent
  • Venous thromboembolism in patients with pemphigus: A cohort study
  • Yael Anne Leshem, Lihi Atzmony, Israel Dudkiewicz, Emmilia Hodak, Daniel Mimouni
| Article suivant Article suivant
  • Gene expression of sphingolipid metabolism pathways is altered in hidradenitis suppurativa
  • Mohammed Dany, Dirk Elston

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.